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Abstract
Background: Caveolin 1 (Cav-1) is the primary structural component of cell membrane invaginations called
‘caveolae’. Expression of Cav-1 is implicated in the pathogenesis of pulmonary fibrosis. Genetic polymorphisms in
the CAV1 gene influence the function of Cav-1 in malignancies and associate with renal allograft fibrosis. Chronic
allograft rejection after lung transplantation, called ‘bronchiolitis obliterans syndrome’ (BOS), is also characterised by
the development of fibrosis.
In this study, we investigated whether CAV1 genotypes associate with BOS and whether Cav-1 serum levels are
influenced by the CAV1 genotype and can be used as a biomarker to predict the development of BOS.
Methods: Twenty lung transplant recipients with BOS (BOS
pos), ninety without BOS (BOS
neg) and four hundred
twenty-two healthy individuals donated DNA samples. Four SNPs in CAV1 were genotyped. Serial Cav-1 serum
levels were measured in a matched cohort of 10 BOS
pos patients and 10 BOS
neg patients. Furthermore, single-time
point Cav-1 serum levels were measured in 33 unmatched BOS
neg patients and 60 healthy controls.
Results: Homozygosity of the minor allele of rs3807989 was associated with an increased risk for BOS (odds ratio:
6.13; P = 0.0013). The median Cav-1 serum level was significantly higher in the BOS
pos patients than in the
matched BOS
neg patients (P = 0.026). Longitudinal analysis did not show changes in Cav-1 serum levels over time
in both groups. The median Cav-1 serum level in the group of 43 BOS
neg patients was lower than that in the
healthy control group (P = 0.046).
In lung transplant recipients, homozygosity of the minor allele of rs3807989 and rs3807994 was associated with
increased Cav-1 serum levels.
Conclusion: In lung transplant recipients, the CAV1 SNP rs3807989 was associated with the development of BOS
and Cav-1 serum levels were influenced by the CAV1 genotype.
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Background
Caveolae are 50- to 100-nm flask-shaped cell membrane
invaginations in which the primary structural compo-
nent is caveolin 1 (Cav-1) [1]. Cav-1 has been found in
many cell types, but is abundantly expressed in endothe-
lial cells, type 1 pneumocytes, epithelial cells, smooth
muscle cells and fibroblasts [2-5]. It has many cellular
functions, including vesicular transport, signal transduc-
tion and cholesterol homeostasis [1,4,6].
Kasper et al. [5] were the first investigators to link
Cav-1 to a fibrotic phenotype in the lungs of rats. Sub-
sequently, studies of the role of Cav-1 in pulmonary
fibrosis in humans were conducted. In patients with
idiopathic pulmonary fibrosis (IPF), Cav-1 mRNA
expression was found to be reduced in epithelial cells
and fibroblasts [7]. In patients with systemic sclerosis,
Cav-1 expression was markedly decreased in tissue of
affected lungs and skin [8]. Knockdown of Cav-1
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sion by normal human lung fibroblasts, whereas
increased Cav-1 expression caused a reduction in col-
lagen [9]. CAV1
-/- mice developed pulmonary and skin
fibrosis [8]. On the other hand, during fibrogenesis,
increased expression of Cav-1 was observed in endothe-
lial cells [5,10]. Taken together, the results of these stu-
dies support a pivotal role for Cav-1 in the fibrogenesis
of the lungs [8,11].
The CAV1 gene is localised on chromosome 7, a
highly conserved region that includes a known fragile
site which is deleted or associated with loss of hetero-
zygosity in a variety of human cancers [12]. Studies that
have addressed whether genetic variations of CAV1
increase propensity towards fibrosis are scarce. Among
kidney transplant donors, a SNP in CAV1 was signifi-
cantly associated with renal allograft fibrosis in two
independent cohorts [13].
After lung transplantation, the major limitation on
long-term survival is the development of chronic
rejection in the form of obliterative bronchiolitis (OB)
or its clinical surrogate marker, the bronchiolitis
obliterans syndrome (BOS) [14]. OB is characterised
by inflammation and remodelling of the pulmonary
epithelium of the small airways [15]. This process
results in the recruitment and proliferation of fibro-
blasts, which ultimately leads to fibrosis. Advanced
OB can include a spectrum ranging from partial to
complete acellular fibrotic obliteration whereby only
scar tissue remains of the airway lumen [16,17].
When BOS is diagnosed on the basis of a decline in
lung function, the process of inflammation and fibro-
sis is usually at an advanced and irreversible stage and
treatment options are limited [15]. This emphasises
the need for biomarkers that predict the development
of BOS before a decline in lung function has
occurred.
The primary objective of this study was to determine
whether SNPs in the CAV1 gene are associated with the
development of BOS after lung transplantation. In addi-
tion, Cav-1 serum levels in controls and lung transplant
recipients were measured to evaluate whether Cav-1
serum levels are influenced by genotype and can be use-
ful as a biomarker to predict the development of BOS.
To establish whether Cav-1 expression is indeed present
in OB lesions, lung tissue sections from BOS
pos patients
and controls were studied using immunohistochemical
staining.
The role of Cav-1 in lung transplant recipients and
BOS has never been investigated. However, the role of
Cav-1 in another pulmonary fibrotic disease, such as
IPF, has been described previously [7]. To improve the
understanding of Cav-1, we also measured Cav-1 serum
levels in patients with IPF.
Results
Genotype and haplotype distribution of CAV1 in patients
and controls
During the study period, 139 lung transplant procedures
were performed in 138 patients. One hundred ten reci-
pients gave their written informed consent and donated
DNA, of whom twenty patients developed BOS during
follow-up (Table 1). The genotype distributions of the
four SNPs in CAV1 in the different groups are reported
in Table 2. All SNPs were found to be polymorphic and
in Hardy-Weinberg equilibrium (HWE). The genotype
distribution of rs3807989 was significantly different
between BOS
pos and BOS
neg patients (P = 0.015), which
is related to a significantly higher minor allele frequency
of rs3807989 in BOS
pos patients than in BOS
neg patients
(minor allele frequency 0.58 vs 0.35; P = 0.027). Homo-
zygotes of this minor allele had an increased risk of
developing BOS compared with carriers of the major
allele (odds ratio, 6.13; P = 0.0013; 95% confidence
interval, 1.85 to 20.41). For the other SNPs, no signifi-
cant differences were found in the genotype distribution
and allele frequency between the patient groups and
healthy controls.
The linkage disequilibrium (LD) structure revealed
one haplotype block between rs3807989 and rs3807994
with D’ =1a n dr
2 = 0.45; therefore, haplotypes of the
CAV1 polymorphisms were constructed and analysed.
Fourteen haplotypes were constructed, and the six most
frequent haplotypes with a frequency exceeding 5% were
Table 1 Baseline characteristics of BOS
pos and BOS
neg
patients and healthy controls
a
Variables BOS
pos BOS
neg Controls
Number of patients 20 90 422
Gender, n (%)
Male 9 (45%) 46 (51%) 228 (54%)
Female 11 (55%) 44 (49%) 194 (46%)
Mean age (± SD), years 53.4 ±
10.7
49.4 ±
12.7
48.2 ±
11.9
Diagnosis, n (%) NA
COPD 7 (35%) 29 (32%)
CF 2 (10%) 24 (27%)
IPF 4 (20%) 13 (14%)
Sarcoidosis 2 (10%) 3 (3%)
a1 antitrypsin deficiency 5 (25%) 7 (8%)
Other 0 14 (16%)
Type of graft, n (%) NA
Unilateral 4 (20%) 13 (14%)
Bilateral 16 (80%) 77 (86%)
Mean time to BOS (± SD),
months
23.7 ±
15.2
NA NA
aBOS
pos, bronchiolitis obliterans syndrome-positive; BOS
neg, bronchiolitis
obliterans syndrome-negative; COPD, chronic obstructive pulmonary disease;
CF, cystic fibrosis; IPF, idiopathic pulmonary fibrosis; NA, not applicable; SD,
standard deviation.
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pos patients had
significantly more homozygotes of haplotype 3 than
BOS
neg patients and controls (P = 0.03).
Cav-1 serum levels in patients and controls
In our cohort of lung transplant recipients, serum sam-
ples were collected from 10 BOS
pos patients and 43
BOS
neg patients (Table 4). Initially, we matched 10 BOS-
pos patients with 10 BOS
neg patients to reduce the
influence of confounding factors and performed longitu-
dinal analysis of Cav-1 serum levels. These patients
were matched for several clinicodemographic variables,
including age, gender and primary lung pathology. Serial
serum samples were used to perform this longitudinal
analysis, and two to five serum samples were collected
for every matched BOS
pos patient and BOS
neg patient.
The median (interquartile range (IQR)) Cav-1 serum
level of all samples in the 10 BOS
pos patients was signifi-
cantly higher than that of the 10 matched BOS
neg
patients: 555 ng/mL (447 to 747) and 468 ng/mL (418
to 558), respectively (P = 0.026) (Figure 1). The median
Cav-1 serum level of healthy controls (n = 60; one sam-
ple per individual) was 609 ng/mL (531 to 678) and dif-
fered significantly from that of all samples from the 20
matched lung transplant recipients (10 BOS
pos and 10
BOS
neg patients): 492 ng/mL (426 to 629) (P = 0.0003)
(Figure 1).
We analysed Cav-1 serum levels in the matched
cohort from the time of lung transplantation until the
BOS diagnosis was made. Samples were selected using a
quadrant-based sampling model. In this model, the fol-
low-up period after lung transplantation until the devel-
opment of BOS was divided into four equal quadrants,
and one sample taken at the midpoint of each interval
was analysed. The samples from the BOS
neg patients
were obtained from chronologically similar visits at
which the samples for their BOS
pos counterparts were
analysed. In the BOS
pos patients, one extra sample was
obtained within two months before the BOS diagnosis
was made. The mean time period between lung trans-
plantation and the onset of BOS was 19 months, with a
variation ranging from 8 to 49 months (Table 4). The
serial Cav-1 serum levels in both groups did not reveal
a significant increase or decrease at similar time points
after lung transplantation and prior to BOS. Because
Cav-1 serum levels did not change over time, the sam-
ples from the first quadrant of this matched cohort were
used for further analysis.
To investigate whether the difference in Cav-1 serum
levels between the matched BOS
pos and BOS
neg patients
would hold in an unmatched BOS
neg group, 33 extra
unmatched BOS
neg patients were added to the cohort of
Table 2 Genotype distribution of BOS
pos and BOS
neg patients and healthy controls
a
BOS
pos (n = 20) BOS
neg (n = 87)
b Controls (n = 422)
SNPs Gene region Major/minor AA AB BB AA AB BB AA AB BB
rs12154695 Unknown C/A 12 (60) 6 (30) 2 (10) 34 (39) 47 (54) 6 (7) 181 (43) 189 (45) 52 (12)
rs10256914 Intron T/C 12 (60) 6 (30) 2 (10) 50 (57) 29 (33) 8 (9) 228 (54) 158 (37) 36 (9)
rs3807989
c Intron C/T 4 (20) 9 (45) 7 (35) 33 (38) 47 (54) 7 (8) 144 (34) 206 (49) 72 (17)
rs3807994 Intron C/T 10 (50) 7 (35) 3 (15) 57 (66) 28 (32) 2 (2) 240 (57) 156 (37) 26 (6)
aAll data are n (%). BOS
pos, bronchiolitis obliterans syndrome-positive; BOS
neg, bronchiolitis obliterans syndrome-negative; A, major; B, minor.
bCAV1 genotyping
failed in three BOS
neg patients.
cGenotype distribution BOS
pos vs BOS
neg: P = 0.015; allele frequency BOS
pos vs BOS
neg: P = 0.027.
Table 3 Haplotype distribution in BOS
pos patients
(n = 20), BOS
neg patients (n = 87) and healthy controls
(n = 422)
a
Haplotypes Homozygotes, n
(%)
Heterozygotes, n
(%)
Carriers, n
(%)
CTCC
BOS
pos 1 (5) 9 (45) 10 (50)
BOS
neg 12 (14) 49 (56) 61 (70)
Controls 61 (14) 218 (52) 279 (66)
CTTC
BOS
pos 1 (5) 4 (20) 5 (25)
BOS
neg 0 (0) 12 (14) 12 (14)
Controls 2 (0.5) 52 (12) 54 (13)
CCTT
b
BOS
pos 2 (10) 3 (15) 5 (25)
BOS
neg 0 (0) 15 (17) 15 (17)
Controls 4 (1) 75 (18) 79 (19)
ATCC
BOS
pos 0 (0) 4 (20) 4 (20)
BOS
neg 0 (0) 20 (23) 20 (23)
Controls 10 (2) 60 (14) 70 (16)
ATTC
BOS
pos 0 (0) 4 (20) 4 (20)
BOS
neg 0 (0) 17 (20) 17 (20)
Controls 4 (1) 76 (18) 80 (19)
ACTT
BOS
pos 0 (0) 1 (5) 1 (5)
BOS
neg 0 (0) 10 (11) 10 (11)
Controls 1 (0.5) 70 (17) 71 (17)
aBOS
pos, bronchiolitis obliterans syndrome-positive; BOS
neg, bronchiolitis
obliterans syndrome-negative;
bBOS
pos vs controls: P = 0.03; BOS
pos vs BOS
neg:
P = 0.03. Sequence of SNPs in haplotype: rs12154695, rs10256914, rs3807989,
rs3807994.
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pos and BOS
neg patients (BOS
neg matched and unmatched) and healthy controls
and patients with idiopathic pulmonary fibrosis
a
Variables BOS
pos BOS
neg (matched) BOS
neg (unmatched) Controls IPF
Total number 10 10 33 60 25
Gender, n
Male 3 4 18 30 18
Female 7 6 15 30 7
Mean age (± SD), years 45.2 ± 15.0 45.7 ± 13.1 48.2 ± 13.9 46.7 ± 11.3 64.7 ± 11.3
Diagnosis, n NA NA
COPD 3 3 8
CF 4 5 10
IPF 1 0 5
Sarcoidosis 1 0 2
a1 antitrypsin deficiency 1 1 3
Other 0 1 5
Type of graft, n NA NA
Bilateral 10 10 27
Unilateral 0 0 6
Survival, mean ± SD, months 33.6 ± 20.0 46.4 ± 9.5 51.6 ± 21.3 NA NA
Mean BOS-free survival (± SD), months 19.3 ± 12.5 46.4 ± 9.5* 51.6 ± 21.3* NA NA
BOS grade at diagnosis, n NA NA NA NA
17
23
30
Histology NA NA NA NA
Biopsy, histological OB 4
Biopsy, no histological OB 2
No biopsy 4
aBOS
pos, bronchiolitis obliterans syndrome-positive; BOS
neg, bronchiolitis obliterans syndrome-negative; * identical to survival; COPD, chronic obstructive
pulmonary disease; CF, cystic fibrosis; IPF, idiopathic pulmonary fibrosis; OB, obliterative bronchiolitis; NA, not applicable; SD, standard deviation.
Figure 1 Caveolin 1 (Cav-1) serum levels in patient groups and healthy controls. Groups: Controls (co, n = 60), the cohort of matched lung
transplant recipients (Ltx) (n = 10 BOS
pos patients and n = 10 matched BOS
neg patients; samples per patient ranged from two to five), BOS
pos
patients (BOS+, n = 10), matched BOS
neg patients (BOS-, n = 10), patients with idiopathic pulmonary fibrosis (IPF, n = 25). Horizontal bars
represent medians.
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neg patients. In these 33 BOS
neg patients, Cav-1
serum levels were measured at one moment after lung
transplantation. We found that the median Cav-1 serum
levels were not significantly different between the 43
BOS
neg patients and 10 BOS
pos patients, respectively:
550 ng/mL (433 to 736) and 565 ng/mL (421 to 738),
respectively (P =0 . 8 9 ) .T h e4 3B O S
neg patients had sig-
nificantly lower Cav-1 serum levels than the controls (P
= 0.046).
To improve the understanding of the role of Cav-1 in
pulmonary fibrosis, Cav-1 serum levels were also mea-
sured in patients with IPF (n = 25; one sample per indi-
vidual). The median Cav-1 serum concentration in this
group was 818 ng/mL (609 to 940), which was signifi-
cantly higher than that in 10 BOS
pos patients (P =
0.0027), 10 BOS
neg patients (P < 0.0001) and controls (P
= 0.0007) (Figure 1).
Correlation of Cav-1 serum levels with genotype and
haplotype
In all lung transplant recipients (10 BOS
pos and 43 BOS-
neg patients), homozygotes of the minor allele of the fol-
lowing SNPs had significantly increased serum levels
compared with the carriers of the major alleles:
rs3807989 (689 vs 520 ng/mL; P = 0.03) and rs3807994
(731 vs 520 ng/mL; P = 0.02) (Figure 2).
Heterozygotes of haplotype 2 (CTTC) had lower Cav-
1 serum levels than heterozygotes of haplotype 3
(CCTT) (448 vs 689 ng/mL; P = 0.04). Also, carriers of
haplotype 2 had lower Cav-1 serum levels than carriers
of haplotype 3 (448 vs 672 ng/mL; P = 0.02) (Figure 3).
Localisation of Cav-1 in obliterative bronchiolitis
Qualitative immunohistochemical staining of Cav-1 was
studied in lung tissue from six lung transplant recipients
and two controls. In normal lung tissue, the Cav-1 stain-
ing was intense in the cell membranes of endothelial
cells and the alveolar epithelium. The Cav-1 staining in
the bronchiolar epithelial cells was less intense (Figure
4, left panel).
In OB lesions, the intensity of the Cav-1 staining in
endothelial cells and alveolar epithelium was similar to
that in normal lung tissue. The staining of Cav-1 in the
bronchiolar epithelium of lung transplant recipients
with OB was slightly accentuated compared with normal
bronchiolar epithelium. In the OB lesions, some staining
of the cellular infiltrate, that is, partially obliterating the
bronchiolus, was observed (Figure 4, right panel).
Discussion
We found an association between a genetic polymorph-
ism in the CAV1 gene and the development of BOS.
Homozygosity of the minor allele of rs3807989 is asso-
ciated with a sixfold increased risk of developing BOS.
Cav-1 serum levels were genotype-dependent. In lung
transplant recipients, increased Cav-1 serum levels were
observed in homozygotes of the minor alleles of two
SNPs, including rs3807989, which genotype was asso-
ciated with an increased risk of BOS.
Cav-1 is an integral protein of caveolae and has been
identified in a wide variety of cells [1]. Although this
protein was originally identified as a membrane protein,
Cav-1 has also been reported to be present in the
Figure 2 Correlation of caveolin 1 serum levels with genotype in lung transplant recipients. Caveolin 1 (Cav-1) serum levels in lung
transplant recipients (10 BOS
pos and 43 BOS
neg patients) are increased in homozygotes of the minor alleles compared with carriers of the major
allele of rs3807989 (P = 0.03) and rs3807994 (P = 0.02). Horizontal bars represent medians.
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vary glands, in differentiating osteoblasts and in cancer
cells [18-21]. This might explain the detectable serum
levels of Cav-1 in healthy controls. Cav-1 serum levels
were never measured before in lung transplant recipi-
ents or in patients with IPF. However, Cav-1 serum
levels in patients with prostate cancer have been shown
to be a potential biomarker in this disease [19,22-24].
We found that Cav-1 in serum was lower in lung trans-
plant recipients than in healthy controls. Within the
matched cohort of 10 BOS
pos and 10 BOS
neg patients,
the BOS
pos patients had higher Cav-1 serum levels than
the BOS
neg patients. The six highest Cav-1 serum levels
in the BOS
pos cohort, illustrated in Figure 1, were mea-
sured in two patients who are both homozygous for the
risk allele of SNP rs3807989. Serial Cav-1 serum levels
Figure 3 Caveolin 1 serum levels in carriers of haplotype 2 and haplotype 3 in lung transplant recipients. Carriers of haplotype 2 (CTTC,
n = 4) had lower caveolin 1 (Cav-1) serum levels compared with carriers of haplotype 3 (CCTT, n =9 )( P = 0.02). The number of individuals is
smaller than reported in Table 3 because serum samples were not available from all BOS
pos and BOS
neg patients. Horizontal bars represent
medians.
 
Figure 4 Immunohistochemical staining for caveolin 1 in lung tissue sections. Left: Control tissue from a lobectomy specimen (left lower
lobe) with positive staining of alveolar epithelium, endothelium and smooth muscle cells and minimal staining of the bronchiolar epithelium.
Right: One representative sample of an obliterative bronchiolitis (OB) lesion from the right lower lobe, with some staining of the cellular infiltrate
partially obliterating the bronchiole. In this sample, the staining of bronchiolar epithelium seems slightly increased. The staining of alveolar
epithelium and endothelium are similar to normal lung tissue. Open arrows indicate the arterial branch. Closed arrows indicate the bronchiole
(original magnification, ×100).
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Page 6 of 11of the matched cohort did not reveal a trend in Cav-1
concentration with time after lung transplantation and
prior to BOS. The total group of 43 BOS
neg patients had
lower Cav-1 serum levels than the healthy controls, but
in contrast to the matched cases there was no difference
in Cav-1 serum concentration between the 10 BOS
pos
patients and the total group of 43 BOS
neg patients. For
these reasons, Cav-1 serum levels cannot be used as a
biomarker to predict the development of BOS.
We also measured Cav-1 serum levels in 25 patients
with IPF. Although the pathogenesis of BOS and IPF
remains to be determined, there may be some similari-
ties. The general hypothesis is that BOS and IPF are
c a u s e db yi n j u r yo ft h el u n gf o l l o w e db ya na b e r r a n t
repair response and ultimately fibrosis [15,25]. During
fibrogenesis in IPF and BOS, the epithelial to mesenchy-
mal transition is a critical cellular mechanism [25,26],
and neutrophils play an important role in both diseases
[27,28]. Differences between these two entities are the
localisation of the lesions in the lung and the stimuli
that cause the initial injury. BOS is localised within the
respiratory bronchioli and IPF is localised within the
alveoli [17,29]. Several immune-dependent and -inde-
pendent mechanisms are known to be risk factors for
the development of BOS [15]. However, the stimuli that
cause the injury in IPF are still unknown [25].
Cav-1 serum levels are significantly increased in
patients with explicit pulmonary fibrosis, as illustrated
by the increased Cav-1 serum levels in patients with IPF
in this study. On the other hand, the expression of Cav-
1 in lung tissue and fibroblasts of patients with IPF was
previously described to be decreased and associated with
enhanced transforming growth factor (TGF)-b1 signal-
ling and increased collagen deposition [2,3,7]. The rela-
tionship between Cav-1 expression in lung tissue and
pulmonary fibroblasts and the Cav-1 serum concentra-
tion is unknown. One can only speculate about the dis-
crepancy between the decreased Cav-1 expression in IPF
described in the literature and the increased concentra-
tion of its soluble form in patients with IPF. Cav-1 is
present in caveolae of the cell membrane, and it might
also be part of secretory pathways, that is, of the pan-
creas or salivary glands, which might influence Cav-1
serum levels [18].
Increased Cav-1 serum levels in BOS
pos patients com-
pared with BOS
neg patients were expected because of
the process of fibrogenesis in BOS. In the matched
cohort, we were able to detect this difference in Cav-1
concentration. The hypothesis that Cav-1 is increased in
BOS
pos patients is supported by the correlation of
rs3807989 minor T allele with both an increased risk of
BOS and increased Cav-1 serum levels. For future stu-
dies, the presence of extremely high Cav-1 serum levels
might be specific to BOS
pos patients.
The increased Cav-1 serum levels in BOS
pos patients
compared with the matched BOS
neg patients may be
explained by TGF-b1. Researchers in several studies
have shown that TGF-b1 is involved in the development
of BOS [30-33], although others could not confirm this
[26,34].
During pulmonary fibrosis, it has been shown that
Cav-1 expression is decreased in epithelial cells and
fibroblasts compared with controls, but is increased in
endothelial cells [5,7,10,35]. We found that Cav-1
expression in normal lung tissue was similar to the find-
ings of Odajima et al. [36], who localised Cav-1 in nor-
mal lung tissue and in lung tissue of patients with
interstitial pneumonias. A description of Cav-1 expres-
sion in OB after lung transplantation is not available.
We found that in OB lesions, Cav-1 expression in the
bronchiolar epithelial cells seemed to be slightly
increased compared with normal lung tissue. In the OB
lesions, cellular infiltrates were observed that showed
some degree of Cav-1 expression and were partially
obliterating the lumen of the bronchiole. These lesions
may represent an early phase in the development of
BOS and might explain the tendency towards an overall
increase in Cav-1 serum levels in BOS
pos patients. In the
development of BOS, fibrointimal changes involving pul-
monary arteries and veins are seen, but they have been
overshadowed by the airway lesions [37].
Cav-1 expression in BOS seems increased, but Wang
et al. [7] found a decreased epithelial expression of Cav-
1 in IPF. The limited number of tissue sections from
BOS
pos patients and the absence of multiple compari-
sons based on image analysis clearly limit the conclu-
sions we can draw from this part of our study.
Pulmonary fibrosis in patients with IPF and systemic
sclerosis is different from that in patients with BOS and
is localised in other parts of the lung. Different cell
types and molecular pathways may be involved in the
pathogenesis of these diseases. Furthermore, there is evi-
dence that different types of caveolae exist and that
there is more than one regulatory mechanism of Cav-1
expression [35]. Two Cav-1 isoforms, a and b,a r e
known, both of which were detected by the antibodies
used in our study [35,38]. The a isoform is mainly
expressed by endothelial cells, and the alveolar cells pre-
dominantly express the b isoform [38]. This underlines
the complexity of Cav-1 in pulmonary pathology.
Regarding the source of the serum Cav-1 in BOS
pos
patients, we hypothesize that the Cav-1 expression in
OB lesions could have a relationship with the increased
serum levels we observed. However, further research
based on quantitative analysis is needed.
The mechanism by which Cav-1 contributes to fibrosis
might be found in the signalling pathway. Cav-1 func-
tions as part of the TGF-b pathway through its
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is involved in the development of fibrosis by stimulation
of extracellular matrix production and accumulation of
collagens and other matrix proteins [2,39]. In addition,
Cav-1 serves as a scaffolding protein for other signalling
molecules, such as members of the mitogen-activated
protein kinase family, G proteins and other growth fac-
tor receptors [40]. These signalling molecules are
involved in the regulation of a-smooth muscle actin-
positive fibroblasts and collagen [40,41].
Some limitations of our study have to be acknowl-
edged. First, the study has a retrospective design and the
number of patients may be too low to detect more
subtle differences in Cav-1 serum levels within the lung
transplant recipients. However, the procedure that we
used to match the BOS
pos and BOS
neg patients might
have reduced the influence of confounding factors.
Additional studies with more lung transplant recipients
and a longer follow-up period are required to replicate
our association between the CAV1 genotype and BOS.
In addition, experimental studies and quantitative analy-
sis using immunohistochemistry need to be conducted
to better understand the molecular mechanisms of Cav-
1 underlying our observations.
Application of the genetic variability of lung transplant
recipients in the management and treatment of these
patients could be a promising approach in the future.
Genetic risk profiling might provide a tool for individua-
lised risk stratification and for personalised immunosup-
pressive treatment after lung transplantation.
Personalised immunosuppressive treatment might lead
to better graft survival and less drug toxicity. The CAV1
genotype of SNP rs3807989 is associated with the devel-
opment of BOS and therefore could be included in such
a genetic risk profile.
Conclusions
Our data demonstrate that the CAV1 SNP rs3807989 is
associated with the development of BOS after lung
transplantation and that Cav-1 serum levels are influ-
enced by the composition of the coding gene. The risk
allele associates with increased Cav-1 serum levels, and
OB lesions might show increased Cav-1 expression. The
mechanism through which increased Cav-1 expression
contributes to the development of BOS needs to be
explored further.
Materials and methods
Patients and clinical data
All lung transplant recipients who underwent transplan-
tation in the Heart Lung Centre of the University Medi-
cal Centre in Utrecht, The Netherlands, in the period
from July 2001 to November 2008 were asked to donate
DNA and serum.
The diagnosis BOS was defined as a decline in forced
expiratory volume in one second (FEV1)o fg r e a t e rt h a n
20% from the baseline determined by average of two
measurements made at least three weeks apart in the
absence of known causes for acutely declining FEV1,
such as acute rejection and infection [16]. Standard
immunosuppressive therapy consisted of basiliximab
(induction), tacrolimus, mycophenolate mofetil and pre-
dnisone for all patients. After approval by the local med-
ical ethics committee, informed consent was obtained
from each lung transplant recipient and healthy control,
and DNA and serum were collected.
Genotyping
Three haplotype-tagging SNPs for the CAV1 gene were
selected using the Tagger programme (Broad Institute,
Cambridge, MA, USA; http://www.broadinstitute.org/
mpg/tagger/) for the genomic region of CAV1 ± 2,500
bp on genome build 35. Preferential picking of SNPs
was conducted under the pairwise tagging options, a
minimum allele frequency setting of 25% and a high
Illumina design score (Illumina; San Diego, CA, USA).
The algorithm was set to select tags that would cover
the Caucasian HapMap panel with an r
2 of 0.8 or more
[42]. Furthermore, additional SNPs were selected on the
basis of previously published data or presumed function-
ality. The following SNPs were genotyped: rs12154695,
rs10256914, rs3807989 and rs3807994.
DNA was extracted from whole-blood samples, and
SNP typing was conducted using a custom-made Illu-
mina GoldenGate bead SNP assay (Illumina) in accor-
dance with the manufacturer’s recommendations. The
characteristics of the lung transplant recipients and con-
trols from whom DNA was taken are shown in Table 1.
In three BOS
neg patients, the genotyping of the CAV1
SNPs failed. The control group comprised 422 healthy
individuals who were not receiving any medical treat-
ment at the time of analysis.
Cav-1 serum levels in patient groups and healthy controls
Cav-1 serum levels were measured in different groups of
lung transplant recipients to perform longitudinal analy-
sis and to investigate whether Cav-1 can be used as a
biomarker for BOS. For longitudinal analysis of Cav-1
serum levels, 10 BOS
pos patients were matched with 10
BOS
neg patients to reduce the influence of confounding
factors. In this matched cohort of 10 BOS
pos patients
and 10 BOS
neg patients, sequential serum samples (ran-
ging from two to five samples per patient) were ana-
lysed. These patients were matched for several
clinicodemographic variables to reduce the influence of
confounding factors, including age (difference in age less
than three years), gender, primary lung pathology, post-
operative follow-up time (difference in postoperative
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bilateral transplantation (Table 4). Patients were
matched on these five items with a median of 4.0
matching items (range, 2.0 to 5.0 items).
A quadrant-based sampling model was used to com-
pare serum Cav-1 levels between the matched BOS
pos
and BOS
neg patients at similar time points after lung
transplantation and prior to BOS as described previously
[43,44]. The time period from lung transplantation until
the diagnosis of BOS was made varied in the cohort of
BOS
pos patients with a mean of 19 months (Table 4).
To investigate whether Cav-1 serum levels are useful as
a biomarker for BOS, Cav-1 serum levels were measured
at one moment in 33 BOS
neg patients who were not
matched with a BOS
pos patient. The baseline character-
istics of these three groups of lung transplant recipients
are summarised in Table 4.
Cav-1 serum levels were measured in 60 healthy con-
trols (Table 4). The minor allele frequencies of the four
SNPs in this cohort were 37% (rs12154695), 30%
(rs10256914), 50% (rs3807989) and 28% (rs3807994). To
improve our understanding of the role of Cav-1 in pul-
monary fibrosis, Cav-1 serum levels were measured in
25 patients with IPF at one time point (Table 4). These
patients were diagnosed according to the current Ameri-
can Thoracic Society/European Respiratory Society
guidelines [45].
Protocol for serum Cav-1 assay
All serum samples were stored at -80°C until analysis.
Serum Cav-1 was measured using the ELISA developed by
Tahir et al. [22] with some minor modifications. Briefly,
Nunc maxisorb microplate wells (Nalgene Nunc Interna-
tional/Thermo Scientific, Rochester, NY, USA) were
coated overnight at 4°C with 100 μL of 0.25 μg/well poly-
clonal anti-Cav-1 antibody (BD Transduction Labora-
tories, San Diego, CA, USA) and blocked with Tris-
buffered saline containing 1.5% BSA and 0.05% vol/vol
Tween 20 (blocking buffer). All incubation was done at
room temperature. To 50 μL of blocking buffer, 50 μLo f
serum samples, calibrators and controls were added. We
used full-length Cav-1 recombinant protein as a calibrator
(Abnova, Taipei City, Taiwan). After shaking, the plate
was incubated for two hours. After washing, 100 μL of 0.1
μg/well monoclonal Cav-1 antibody (BD Transduction
Laboratories) were incubated for 90 minutes, followed by
60 minutes of incubation with 100 μLo f0 . 1 3μg/well poly-
clonal rabbit antimouse horseradish peroxidase (Dako,
Glostrup, Denmark). After washing, 90 μL of 3,3’,5,5’-tet-
ramethylbenzidine substrate solution (BioLegend, San
Diego, CA, USA) were added and the blue colour was
allowed to develop for 20 minutes in the dark. The reac-
tion was stopped by adding 50 μLo f2NH 2SO4, and the
absorbance was read at 450 nm using a microplate reader
(BioTek, Winooski, VT, USA).
Immunohistochemistry of human lung tissue sections
Paraffin-embedded tissue was available from six BOS
pos
patients (lung biopsy, autopsy or lung explant). Excess
tissue of a lung donor and an area of normal lung tissue
from a lobectomy specimen were used as healthy
controls.
Serial cross-sections (4 μm) were deparaffinized and
rehydrated, boiled in sodium citrate and blocked in 10%
normal goat serum. The sections were incubated for
one hour at room temperature with 1.25 μg/mL polyclo-
nal rabbit antihuman Cav-1 antibody (BD Transduction
Laboratories) as determined by titration, and analysed
using the Novocastra PowerVision Poly-HRP Anti-Rab-
bit IHC Detection System (Leica Microsystems, Buffalo
Grove, IL, USA). Staining was developed with 3,3’-dia-
minobenzidine substrate and counterstained with hae-
matoxylin. Negative controls were obtained by avoiding
the primary antibody.
Statistical analysis
The statistical significance of the differences between
groups was determined by using the c
2 test and one-
way analysis of variance. HWE and tests for association
were calculated using the online programme available at
http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl.
The HWE cutoff for significant disequilibrium and sub-
sequent exclusion from analysis was set at P = 0.05.
The significance threshold was set after accounting for
multiple comparisons using a Bonferroni correction for
the effective number of independent SNPs proposed by
Li and Ji [46]. Owing to LD, the effective number of
SNPs was three for CAV1, resulting in an adjusted sig-
nificance threshold of 0.05/3 = 0.017. Therefore, P
values were multiplied by three to adjust for multiple
comparisons. Thus, P values ≤ 0.05 were considered sta-
tistically significant.
The LD structure of the polymorphisms was deter-
mined using Haploview 4.2 software [47]. Haplotypes
were reconstructed using the PHASE software pro-
gramme [48].
Cav-1 serum levels were not normally distributed and
are expressed as medians with IQRs. To determine
whether there was a trend in serial serum levels over
time in a single subject, and to compare this trend
between the two groups, a restricted maximum likeli-
hood linear mixed model was used [49]. The Mann-
Whitney U test was applied to comparisons between
genotype and serum levels. Statistical analyses were per-
formed using SPSS for Windows version 17.0 software
(SPSS Inc, Chicago, IL, USA).
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